ARV-393 shows promising antitumor effects in combination with standard therapies for non-Hodgkin lymphoma, warranting further investigation.

ARV-102 is a novel investigational oral PROTAC designed to cross the blood-brain barrier and target LRRK2. While LRRK2 is primarily known for its role in PD, emerging evidence suggests that it ...

Arvinas will present preclinical data on ARV-393's potential in lymphoma treatment at the AACR Annual Meeting.

Arvinas Inc. (NASDAQ:ARVN) is one of the best low priced pharma stocks to buy now. Earlier on June 13, Arvinas presented encouraging preclinical data for its investigational PROteolysis TArgeting ...